Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
304,7 USD | -0,10% | -0,88% | +5,80% |
Vakgebied
- geneesmiddelenverkoop (94,2%): geneesmiddelen voor de behandeling van kanker, stofwisselingsstoornissen, botziekten, nierfalen, hemofilie, enz;
- overige (5,8%): voornamelijk royalty's.
De Verenigde Staten zijn goed voor 70,3% van de netto-omzet.
Aantal werknemers: 26 700
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8,50% |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15,90% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6,51% |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8,91% |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35,62% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01-06-06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23-10-19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01-01-07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01-01-15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-01-05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-06-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03-02-17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14-10-16 |
Robert Eckert
BRD | Director/Board Member | 69 | 01-01-03 |
Amy Miles
BRD | Director/Board Member | 57 | 23-07-20 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01-06-06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24-10-17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01-01-12 |
Brian Druker
BRD | Director/Board Member | 68 | 23-05-18 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30-07-21 |
Greg Garland
BRD | Director/Board Member | 66 | 16-10-13 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 536 434 692 | 535 101 988 ( 99,75 %) | 0 | 99,75 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
BEIGENE, LTD. 19.79% | 246 269 426 | 19.79% | 2 787 444 827 $ |
NEUMORA THERAPEUTICS, INC. 22.17% | 35 368 653 | 22.17% | 350 149 665 $ |
4 910 000 | 5.46% | 92 062 500 $ | |
VIGIL NEUROSCIENCE, INC. 8.53% | 3 206 281 | 8.53% | 10 195 974 $ |
100 993 | 0.67% | 2 621 778 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The company is located in Bermuda. |
Biotechnology
|
Amgen Manufacturing Ltd. (Bermuda)
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,80% | 163 mld. | |
+48,39% | 779 mld. | |
+40,51% | 631 mld. | |
-6,13% | 354 mld. | |
+20,61% | 333 mld. | |
+10,00% | 301 mld. | |
+16,58% | 249 mld. | |
-1,68% | 216 mld. | |
+10,89% | 214 mld. | |
-2,50% | 159 mld. |
- Beurs
- Aandelen
- Koers AMGN
- Onderneming Amgen Inc.